中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
UPCOMING EVENTS
News
Careers
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Boyle, JG, et al., Clinical Science (2018) 132 1699–1709
Publications
Title
Venue
Type
Date
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study
The 61st European Association for the Study of Diabetes
(EASD 2025)
Short Oral Presentation
9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study
The 32nd European Congress On Obesity (ECO 2025)
Guided poster
5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice
The 32nd European Congress On Obesity (ECO 2025)
Oral
5/2025
浙公网安备 33010802003344号
浙ICP备11050387号-1